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Complete inhibition of Cdk/cyclin
by one molecule of p21Cip1
Ludger Hengst,1,2 Ulrich Go¨pfert,1 Hilal A. Lashuel,3 and Steven I. Reed2–4
1Max-Planck-Institut fu¨r Biochemie, D-82152 Martinsried, Germany; 2Department of Molecular Biology and 3The Skaggs
Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037 USA
Cell-cycle phase transitions are controlled by cyclin-dependent kinases (Cdks). Key to the regulation of these
kinase activities are Cdk inhibitors, proteins that are induced in response to various antiproliferative signals
but that can also oscillate during cell-cycle progression, leading to Cdk inactivation. A current dogma is that
kinase complexes containing the prototype Cdk inhibitor p21 transit between active and inactive states, in
that Cdk complexes associated with one p21 molecule remain active until they associate with additional p21
molecules. However, using a number of different techniques including analytical ultracentrifugation of
purified p21/cyclin A/Cdk2 complexes we demonstrate unambiguously that a single p21 molecule is
sufficient for kinase inhibition and that p21-saturated complexes contain only one stably bound inhibitor
molecule. Even phosphorylated forms of p21 remain efficient inhibitors of Cdk activities. Therefore the level
of Cdk inactivation by p21 is determined by the fraction of kinase complexed with the inhibitor and not by
the stoichiometry of inhibitor bound to the kinase or the phosphorylation state of the Cdk inhibitor.
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In eukaryotic cells all major cell-cycle transitions are
controlled by the regulation of the activity of cyclin-
dependent kinases (Cdks) (Nigg 1995). In their simplest
form, these kinases are composed of a catalytic subunit,
termed Cdk and a positive regulatory subunit, termed
cyclin (Morgan 1995; Pines 1995). The activity of Cdk/
cyclin complexes can be negatively regulated by various
mechanisms including binding of specific inhibitory pro-
teins (CKIs) (Morgan 1995; Nigg 1995). The prominent
physiological role these inhibitors play is underscored by
the observation that numerous antiproliferative signals
lead to increased CKI levels and that cells deficient for
expression of specific CKIs exhibit defects in cell-cycle
control (Sherr and Roberts 1995; Harper 1997; Carnero
and Hannon 1998; Hengst and Reed 1998). Two families
of CKIs have been described in mammalian cells.
Whereas the Ink4 family inhibitors bind specifically to
kinases Cdk4 and Cdk6, the Cip/Kip family is inhibitory
to a broad range of Cdk/cyclin complexes (Carnero and
Hannon 1998). This second family consists of three pro-
teins, p21, p27, and p57 (Hengst and Reed 1998).
p21Waf1/Cip1/Sdi1/CAP20, the founding member of this
family, is induced in a p53 dependent manner in re-
sponse to DNA damage, accounting for cell-cycle arrest
in G1 (Sherr and Roberts 1995; Hengst and Reed 1998).
Elevated p21 levels have also been observed in cells dur-
ing senescence and differentiation (Sherr and Roberts
1995; Hengst and Reed 1998). Surprisingly for a protein
that can lead to a block in cell-cycle progression, p21
expression was found to be induced when quiescent cells
were stimulated to proliferate (Li et al. 1994; Noda et al.
1994) and moreover the majority of Cdk complexes have
been reported to be in complex with p21 even in prolif-
erating cells (Zhang et al. 1994a,b; Harper et al. 1995). To
explain this apparent paradox, a model has been pro-
posed suggesting that kinase complexes associated with
only one inhibitor molecule remain active and that the
inactivation of Cdk kinase complexes by p21 requires
association with more than one inhibitor molecule
(Zhang et al. 1994a,b; Harper et al. 1995). This model has
been supported by studies demonstrating that Cdk com-
plexes immunoprecipitated with p21 antibodies are ‘ ki-
nase active ’ (Zhang et al. 1994a,b; Harper et al. 1995) and
can be inhibited by addition of excess p21 (Zhang et al.
1994a,b; Harper et al. 1995).
The amino-terminal Cdk-inhibitory domain of p21
shares an extended degree of sequence identity with the
Cdk-inhibitory domain of a related inhibitor, p27 (44%
identity in a region of 60 amino acids). It has been shown
that the amino-terminal domains of both proteins are
sufficient for Cdk inhibition (Toyoshima and Hunter
1994; Chen et al. 1995; Luo et al. 1995). In the course of
analyzing inhibition of cyclin A/Cdk2 by p27, we dis-
covered that a single p27 molecule was sufficient for
inhibition of one kinase complex (L. Hengst and S.I.
Reed, unpubl.). This result was consistent with the
three-dimensional structure of a complex of truncated
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cyclin A/Cdk2/p27 polypeptides determined by X-ray
diffraction crystallography (Russo et al. 1996).
To elucidate the apparent mechanistic difference in
Cdk inhibition by p21 and p27, we investigated the in-
hibition of cyclin A/Cdk2 by p21. To avoid potential
artifacts associated with deletions of domains that might
contribute to protein interactions, truncated proteins
were not used in any of the studies described. We first
analyzed bacterially expressed p21 by sedimentation
equilibrium analytical ultracentrifugation to ensure it
was monomeric under the buffer conditions used for in-
hibition studies. The concentration distribution data of
p21 in the centrifugal field fit to a single ideal species
model with a molecular mass of 18,490 ± 772 dalton)
(Fig.1), corresponding to a monomeric species (the calcu-
lated molecular mass of the HIS-6 tagged p21 is 18,914
daltons).
The monomeric p21 was adsorbed to protein A–Sepha-
rose beads via anti-p21 antibodies (directed against a car-
boxy-terminal peptide known to be dispensable for inhi-
bition). This immobilized monomeric p21 was incubated
subsequently with recombinant, full-length, purified and
activated cyclin A/Cdk2 to form trimeric, p21-bound ki-
nase complexes on beads. If a stoichiometry of more than
one inhibitor molecule per kinase complex were needed
for inhibition, the p21-associated Cdk complexes should
remain kinase active. The kinase activity of the p21
bound complexes was determined and compared to the
activity of noninhibited kinase complexes precipitated
directly with anti-cyclin A antibodies and protein
A–Sepharose. Normalized for kinase polypeptides, only
6% of the kinase activity of non-p21-bound complexes
was retained in complexes bound to p21 beads (Fig. 2, cf.
bars 2 and 4). This remaining kinase activity could be
reduced slightly to 3% by addition of a twofold excess of
soluble p21 protein (Fig. 2, bar 3). These data suggest that
a single, bead-associated p21 molecule almost com-
pletely inhibits a Cdk complex.
To exclude a possible dimerization of p21 molecules
when bound to the beads, we repeated the experiment
with a fourfold lower density of p21 on the beads (Fig. 2,
lane 1). Under these conditions, slightly less cyclin
A/Cdk2 bound to the p21 beads, indicating that here the
amount of immobilized p21 becomes limiting. Again, we
found strong inhibition of the kinase activity, most con-
sistent with the conclusion that a single p21 monomer is
sufficient to inhibit a cyclin A/Cdk2 kinase complex.
Whereas the remaining activity in this experiment (11%)
was slightly higher than that in the experiment using
more p21 (6%), this is probably because of dissociation
and rebinding of the kinase during the assay (see below).
To rule out steric effects of the antibodies used for
immobilization of p21, we investigated the inhibition of
purified cyclin A/Cdk2 kinase by p21 in solution. Cyclin
Figure 2. Inhibition of cyclin A/Cdk2 by immobilized p21.
(lanes 1–3) or anti-cyclin A (lane 4) antibodies were bound to
protein A–Sepharose beads. These beads were incubated with
varying amounts of purified p21: (lane 1) 0.05 µg; (lane 2) 0.2 µg;
(lane 3) 0.2 µg; (lane 4) 0 µg. All beads were washed and incu-
bated with ~ 0.2 µg cyclin A/Cdk2. Nonbound kinase was re-
moved from the beads and the sample of lane 3 was incubated
subsequently with additional 0.4 µg of p21. The nonbound p21
was removed and the kinase activities associated with all
samples were determined using [g-32P]ATP and histone H1 as
substrates. (Left) The amount of precipitated p21 protein (anti-
p21) and Cdk2 (anti-PSTAIRE) was determined in Western blots
using monoclonal antibodies. The level of 32P incorporation in
the histone H1 bands (histone H1) was determined after SDS-
PAGE by autoradiography of the dried gel. The amount of 32P
incorporation in the histone H1 bands shown in this autoradio-
graph was measured using a PhosphorImager. The quantities of
precipitated cyclin A and Cdk2 were determined by densitomet-
ric scanning of anti-PSTAIRE and anti-cyclin A Western blots
and the histone H1 kinase activity of the samples is shown after
normalization for the amount of precipitated kinase protein
(right).
Figure 1. Free p21 is a monomer. The buoyant molecular mass
of recombinant p21 was determined by sedimentation equilib-
rium analytical ultracentrifugation and is 18,490 ± 772 daltons.
A scan after 30 hr is shown. (Bottom) The raw concentration
data determined using interference optics and the solid line
drawn through the data points was obtained by fitting the fringe
displacement vs. radial position to a single species model of
equation 1 (see Materials and Methods). (Top) The residual dif-
ference between the experimental data and the fitted data for
each point shown.
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A/Cdk2 elutes from a gel-filtration column with a
Stokes’ radius of 4.72 nm and, thus, an apparent molecu-
lar mass >84,955 dalton calculated for the heterodimeric
complex of one molecule each of cyclin A and Cdk2 (Fig.
3). However, using analytical ultracentrifugation for
equilibrium sedimentation and velocity sedimentation
analysis, we found that the buoyant molecular mass for
the purified cyclin A/Cdk2 was 86,064 ± 2105 daltons,
and is in excellent agreement with the calculated mass
(Fig. 4).
Next, we wished to determine how many p21 mol-
ecules can associate with a cyclin A/Cdk2 complex in
solution. To saturate all possible binding sites for p21 on
cyclin A/Cdk2, we incubated the kinase complex with
an excess of the inhibitor. Nonbound p21 was separated
from the complex by gel-filtration chromatography (see
Fig. 3, bottom, fractions 20–22). The Cdk/p21 complexes
appeared homogeneous, as the peak and flanking frac-
tions showed an identical ratio of p21 to cyclin A/Cdk2
(Fig. 3, bottom, lanes 11–14). This was confirmed by sedi-
mentation velocity analytical ultracentrifugation, as
p21/cyclin A/Cdk2 sedimented as a single boundary
across the cell, in an excellent fit with a single sediment-
ing species model (data not shown). To determine
whether one or two p21 molecules were bound in this
complex, we determined the buoyant molecular mass of
the purified p21-containing kinase (shown in Fig. 6A,
below) by analytical ultracentrifugation using equilib-
rium sedimentation. The concentration distribution
data fit to a single species model (Fig. 5, solid line), and
the molecular mass of the complex was determined to be
105 kD, which is consistent with the presence of a single
p21 molecule bound per kinase complex (the calculated
molecular mass of this complex is 104 kD). Considering
that the maximum error in the determination of the mo-
lecular mass in this experiment is ±9 kD, the result is
not consistent with a stoichiometry of more than one
p21 molecule per Cdk/cyclin complex. To demonstrate
this, a theoretical curve modeled to two molecules of
p21 per complex is superimposed as a dashed line. It is
apparent from comparative fits to the data points and the
analysis of residual differences between experimental
and fitted data shown above, that the data are much
more compatible with a 1:1:1 stoichiometry. From this,
we conclude that only a single p21 can stably bind to
cyclin A/Cdk2. However, we can not exclude that addi-
tional p21 molecules might interact with cyclin A/Cdk2
transiently without forming a stable complex.
To determine whether the single p21 molecule in
these complexes is sufficient for inhibition, we com-
pared the kinase activities of purified cyclin A/Cdk2 and
p21/cyclin A/Cdk2 complexes in solution. The relative
concentration of the complexes was estimated by Coo-
massie blue staining of the separated proteins after SDS-
PAGE (Fig. 6A). Only 9% of the activity determined for
noninhibitor-bound kinase was found to be associated
with the p21-bound kinase (Fig 6B,C). Therefore, one
Figure 3. Size-exclusion chromatography of cyclin A/Cdk2
(top) and p21-saturated complexes of cyclin A/Cdk2 (bottom).
Proteins were resolved on a Superdex 200 FPLC column. Ali-
quots of each fraction were analyzed by SDS-PAGE and stained
using Coomassie blue. The migration of size standards are
shown at the left on the gel, and the elution behavior, the Stokes
radius, and the apparent molecular mass of marker proteins
separated on this column are shown above.
Figure 4. Determination of the molecular mass of purified cy-
clin A/Cdk2 by sedimentation equilibrium centrifugation. The
apparent molecular mass of the cyclin A/Cdk2 kinase complex
was determined as 86 ± 2 daltons. (Bottom) The raw concentra-
tion data determined by measuring the absorbance at 235 nm
(cyclin A/Cdk2). The solid line drawn through the data points
was obtained by fitting the fringe displacement vs. radial posi-
tion to a single-species model. (Top) The residual differences
between the experimental data and the fitted data for each
point. The purified proteins used for analytical ultracentrifuga-
tion are shown in Fig. 6. Sedimentation equilibrium analysis
was performed at 4°C and a rotor speed of 10,000 rpm.
Hengst et al.
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molecule of p21 inhibits a cyclin A/Cdk2 complex effi-
ciently.
Yet, a low residual activity was observed consistently
when the activity of p21-bound kinase was determined.
Two possible explanations account for this. First, inhib-
ited complexes might retain an intrinsic kinase activity
of ~ 10% of that of the noninhibited complexes. If this
were the case, dilution of inhibited kinase complexes
should not affect the measurable kinase activity. On the
other hand, the residual kinase activity of p21-associated
complexes could reflect a dissociation/reassociation
equilibrium of the kinase complex from the inhibitor
during the kinase assay. In this case, it would be ex-
pected that the residual kinase activity of p21-saturated
cyclin A/Cdk2 would increase if these complexes were
diluted prior to a kinase activity assay. The increase in
kinase activity upon dilution would result from the
lower concentration of p21 available for rebinding of the
dissociated active kinase. We found that dilution of p21/
cyclin A/Cdk2 complexes can lead to a significant loss
of inhibition by p21. As shown in Figure 7, a 10-fold
dilution of inhibited, purified p21/cyclin A/Cdk2 com-
plexes under a threshold level led to a dramatic decrease
in inhibition. The kinase activity of the diluted complex
rose from 9% to nearly 40% of the activity determined
for noninhibitor-bound kinase in the same dilution (Fig.
7B). Because the increase of apparent p21-associated ki-
Figure 5. Determination of the molecular mass of
purified p21/cyclin A/Cdk2 complexes. The apparent
molecular mass of cyclin A/Cdk2 complex increases
from 86 to 105 kD after saturation of the complex
with p21. (Bottom) The raw concentration data deter-
mined by measuring the absorbance at 280 nm. The
solid line drawn through the data points was obtained
by fitting the fringe displacement vs. radial position
to a single-species model. The dashed line represents
the predicted behavior of a 1:1:2 (cyclin A:Cdk2:p21)
complex using the same single-species model. (Top
panels) The residual differences between the experi-
mental data and the fitted data for each point, with
those corresponding to the 1:1:2 model placed above
those corresponding to the 1:1:1 model. The purified
proteins used for analytical ultracentrifugation are
shown in Fig.6. Sedimentation equilibrium analysis
was performed at 4°C and a rotor speed of 9,000 rpm.
Figure 6. p21/Cyclin A/Cdk2 complexes are kinase inactive.
(A) Purified cyclin A/Cdk2 complexes (lane 1) and p21/cyclin
A/Cdk2 complexes (lane 2) were separated by SDS-PAGE and
stained with Coomassie brilliant blue to estimate relative con-
centrations of their polypeptides (A). Size markers are shown at
the sides. The kinase activities of diluted samples (1:100) were
determined using [g-32P] ATP and histone H1 as substrates.
The amount of 32P incorporation in the histone H1 bands is
shown after SDS-PAGE by autoradiography (bottom) (B) and
determined using a PhosphorImager (C). Kinase activities are
shown as percentage of that of the noninhibited complexes and
were normalized for the kinase subunits present in the com-
plexes. (C).
Cdk inhibition by one p21 molecule
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nase activity is obtained without a change in the ratio of
p21 to cyclin A/Cdk2, dissociation of kinase without
efficient reassociation must account for the loss of inhi-
bition. The degree of residual kinase activity is therefore
most likely dependent on the concentration of the pool
of unbound p21 that is present or accumulates during the
kinase assay. Such considerations need to be factored
into the interpretation of kinase assays that are based on
immunoprecipitations of CKI or Cdks from cell lysates.
In addition to its role as a CKI, p21 has also been sug-
gested to be a substrate for Cdks. Phosphorylation of p21
might potentially alter its ability to bind and inhibit ki-
nase complexes. Phosphorylation of a Cdk-inhibitor by
its target Cdk was previously described for p27. When
p27 is incubated with cyclin E / Cdk2 kinase, a phos-
phorylation of the inhibitor on threonine residue 187
was observed, resulting in the elimination of p27 from
the cell (Sheaff et al. 1997; Vlach et al. 1997).
There are three potential minimal Cdk-consensus
phosphorylation sites in the p21 primary structure. Two
forms of different electrophoretic mobility have been ob-
served previously in cyclin A complexes immunopre-
cipitated from G2/M cells (Dulic et al. 1998). To analyze
whether p21 is a substrate of cyclin A/Cdk2, purified
p21 was incubated with cyclin A/Cdk2 for an extended
period of time. At equimolar stoichiometries of p21 and
cyclin A/Cdk2, a phosphorylation event was observed
that led to a minor mobility shift of p21 analyzed by
SDS-PAGE. This phosphorylation event could be fol-
lowed most easily by incorporation of radioactive phos-
phate into p21 (data not shown). Incubation with an ex-
cess of kinase led first to the minimally shifted form of
p21 that appeared with rapid kinetics (within 15 min of
incubation), which was subsequently chased to two ad-
ditional more slowly migrating forms of p21 (data not
shown). Using extended incubation times, all of the p21
could be shifted to these novel forms of lower electro-
phoretic mobility, corresponding to apparent molecular
masses of ~ 23 and 25 kD vs. 21 kD for the unmodified
protein (Fig. 8). These more slowly migrating forms most
likely contain several phosphorylated residues per p21
molecule and were analyzed for Cdk inhibition.
When immobilized using antibodies against the car-
boxy-terminal sequence of p21 and bound to protein
A–Sepharose beads, phosphorylated p21 was able to bind
cyclin A/Cdk2. Using similar amounts of modified and
nonphosphorylated p21, similar amounts of soluble cy-
clin A/Cdk2 were adsorbed (Fig. 8).
Moreover, phosphorylated p21 is a potent inhibitor of
Cdk activity with an inhibition efficiency similar to that
of the nonmodified p21 (Fig. 8; >98% inhibition in each
case). To exclude a possible dimerization of p21 mol-
ecules when bound to the beads, we repeated the experi-
ment with a fourfold lower density of p21 molecules on
the beads. Again, we found strong inhibition of the ki-
nase activity using both forms of p21 (data not shown),
only consistent with the conclusion that a single p21
Figure 7. Inhibition by p21 is lost when inhibited kinase com-
plexes were diluted under a threshold level. The complexes
shown in Fig. 5A were diluted 1:1000 (left) and 1:10,000 (right).
Kinase activities of p21-bound cyclin A/Cdk2 (+) were com-
pared to that of noninhibited kinase (−) using [g-32P] ATP and
histone H1 as substrates. (A) The amount of 32P incorporation in
the histone H1 bands is shown after SDS-PAGE by autoradiog-
raphy (A). Two different exposures of the same gel are shown.
The exposure time shown for the 10-fold diluted samples (1:
10,000) is 10 times longer than that for the concentrated sample
(1:1000). (B) Histone H1 kinase activities of all samples were
determined using a PhosphorImager and the kinase activities of
p21-inhibited kinase are shown as a percentage of that of non-
inhibited kinase and are normalized to the relative kinase sub-
unit concentrations (B).
Figure 8. Phosphorylated p21 is a potent Cdk inhibitor. Phos-
phorylated p21 was obtained by incubating the inhibitor with
an excess of activated cyclin A/Cdk2 and 1 mM ATP. Phos-
phorylated (p21-P) and mock-incubated, nonphosphorylated p21
(p21) were purified and immobilized on protein A–Sepharose
beads as described in Fig. 2. These beads and anti-cyclin A an-
tibodies bound to control beads were incubated with 250 ng of
active cyclin A/Cdk2 complex and washed and equal aliquots
were analyzed for associated kinase activities (histone H1 ki-
nase) and the amount of precipitated proteins. Precipitated pro-
teins were detected after SDS-PAGE and Western blotting and
analyzed for precipitated kinase subunit Cdk2 (Cdk2,
a-PSTAIRE) and inhibitor p21 (p21, a-p21). The phosphorylated
forms of p21 show a lower electrophoretic mobility compared to
nonmodified p21. Precipitated kinase activities associated with
these samples were determined in assays using [g-32P]ATP and
histone H1 as substrate and detected after SDS-PAGE by auto-
radiography of the dried gel (histone H1 kinase).
Hengst et al.
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monomer is sufficient to inhibit a cyclin A/Cdk2 kinase
complex even if p21 is phosphorylated.
Materials and methods
Protein expression and purification
p21 was expressed in Escherichia coli as a carboxy-terminal
6-His–tagged protein as described earlier (Kriwacki et al. 1996).
The His6 tag does not interfere with the inhibitory properties of
p21 (Kriwacki et al. 1996). p21 was isolated from inclusion bod-
ies by denaturing the insoluble proteins in 8 M urea and purified
as a denatured protein using Ni-NTA affinity chromatography
(Quiagen) and Hi-Trap Q column (Pharmacia). The protein was
renatured after binding to a Hi-Trap SP column (Pharmacia) and
further purified by size-exclusion chromatography in buffer con-
taining 200 mM NaCl and 50 mM Tris-HCl at pH 7.2 on a Su-
perose 12 column (Pharmacia).
Cdk2 and cyclin A were expressed using baculovirus and in-
sect cells as unmodified (Cdk2) and amino-terminal 6-His-
tagged (cyclin A) full-length proteins. The baculovirus con-
structs were a gift of D. Morgan (University of California, San
Francisco). Using a Dounce homogenizer, cyclin A and Cdk2
were extracted in buffer containing 10 mM sodium phosphate
(pH 8.0), 300 mM NaCl, 10% (vol/vol) glycerol, 4 mM AEBSF
(PEFA block, Boehringer Mannheim), 1 µg/ml E64, 1 µg/ml pep-
statin, and 1 µg/ml leupeptin. The cyclin A/Cdk2 kinase com-
plex was formed in vitro and activated in the presence of 10 mM
MgCl2, 4 mM ATP, and phosphatase inhibitors during a 45-min
incubation with insect cell extracts containing baculovirus ex-
pressed cyclinH/Cdk7. The cyclin A/Cdk2 complex was then
purified using Ni-NTA affinity chromatography, anion-ex-
change chromatography, and Superdex 200 size-exclusion chro-
matography.
Fast-performance liquid chromatography on a Superdex 200
column was performed at a flow rate of 1 ml/min in chroma-
tography buffer (50 mM Tris-HCl at pH 7.5, 200 mM NaCl) and
0.5-ml fractions were collected. Standards for the gel-filtration
column were gamma globulin (apparent molecular mass in gel
filtration 205 kD, Stokes radius 53 Å) (Andrews 1970), alcohol
dehydrogenase (150 kD, 45 Å) serum albumin (66 kD, 35.5 Å),
ovalbumin (43 kD, 27.3 Å), and myoglobin (17.8 kD, 20.7 Å)
(Andrews 1970).
Immunoprecipitations and kinase activity analysis
p21-containing complexes were immunoprecipitated using an
antibody raised against a carboxy-terminal domain of the pro-
tein (C19, Santa Cruz). Cyclin A was precipitated using the
polyclonal antibody T310 described previously (Hengst et al.
1994). Immunoprecipitations and Western blots have been de-
scribed elsewhere (Hengst et al. 1994). Kinase assays were per-
formed at 30°C for 30 min in kinase assay buffer (50 mM Tris-
HCl at pH 7.2, 10 mM MgCl2) containing histone H1, ATP (as
indicated or 200 µM), [g-32P]ATP, as described earlier (Hengst et
al. 1994).
Analytical ultracentrifugation
Sedimentation equilibrium analysis was performed on a tem-
perature-controlled Beckman XL-I analytical ultracentrifuge
equipped with a An60Ti rotor and photoelectric scanner at 20°C
(p21) or 4°C (p21/cyclin A/Cdk2 and cyclin A/Cdk2 complexes)
at rotor speeds of 17,000 rpm (p21), 10,000 rpm (cyclin A/Cdk2),
or 9000 rpm (p21/cyclin A/Cdk2). Scans were performed using
interference optics (p21) or by measuring the absorbance at 280
nm (p21/cyclin A/Cdk2) or 235 nm (cyclin A/Cdk2), with a
step size of 0.001 cm and 25 averaged scans. Samples were al-
lowed to equilibrate for 24 hr and duplicate scans 3 hr apart
were overlaid to determine that equilibrium had been reached.
The partial specific volume of p21 (0. 73 ml/gram) or the protein
complexes was calculated based on the amino acid composition
and then adjusted for temperature using the Origin software
provided by Beckman. The data were analyzed by a nonlinear
least squares analysis using the Origin software provided by
Beckman and then fit to a single ideal species model using the
following equation:
Ar = Exp @ln~A0! + ~Mv
2~1 - yr!/2RT! ? ~x2 - x0
2!# + E (1)
where Ar is the fringe displacement at radius x a0 is the fringe
displacement at a reference radius x0, y is the partial specific
volume of p21 or the protein complexes, r is the density of the
solvent, v is the angular velocity of the rotor, E is the baseline
error correction factor, M is the molecular weight, and R is the
universal gas constant.
Analysis of phosphorylated p21
p21 (1.5 µg; protein concentrations were estimated after SDS-
PAGE and Coomassie brilliant blue staining) were incubated for
1.5 hr with 20 µg of activated Cdk2/cyclin A in a buffer con-
taining 20 mM Tris/HCl, 140 mMNaCl, 7.5 mM MgCl2, 1 mM
ATP, and 1× Complete protease inhibitors without EDTA
(Boehringer Mannheim) in a reaction volume of 60 µl. As a
control, p21 was mock incubated in the presence of ATP but
without addition of Cdk.
Phosphorylated and mock-incubated p21 were dissociated
and separated from kinase complexes by heat treatment (95°C,
5 min) and immunoprecipitated using a polyclonal anti-p21 an-
tibody, directed against a carboxy-terminal sequence of p21 (C-
19, Santa Cruz Biotechnology). Immunecomplexes were recov-
ered using protein A–Sepharose beads (CL4B, Sigma). p21 bound
to the beads was incubated with 250 ng of recombinant purified
activated cyclin A/Cdk2. It was estimated that p21 or phos-
phorylated p21 were in a twofold molar excess over the enzyme.
To determine noninhibited kinase activities, 250 ng Cdk2/cy-
clin A were precipitated using a polyclonal anti-cyclin A anti-
serum (T310), immobilized on protein A–Sepharose beads and
analyzed as the p21-bound kinase. Beads were washed twice
with IP buffer and once with reaction buffer (20 mM Tris/HCl at
pH 7.2, 7.5 mM MgCl2). Matrix-bound proteins were either ana-
lyzed by SDS-PAGE and Western blotting or tested for their
associated histone H1 kinase activities as described above.
Acknowledgments
We thank David Morgan for the gift of baculovirus expressing
cyclin A, cyclin H, Cdk2, or Cdk7; Jeffery Kelly for providing
use of the analytical ultracentrifuge; and Frauke Melchior for
critical reading of the manuscript. This work was supported by
a fellowship from the Leukemia Society of America to L.H. and
by U.S. Public Health service grant GM46006 and U.S. Army
grant DAMD17-94-J4208 to S.I.R.
The publication costs of this article were defrayed in part by
payment of page charges. This article must therefore be hereby
marked ‘advertisement’ in accordance with 18 USC section
1734 solely to indicate this fact.
Cdk inhibition by one p21 molecule
GENES & DEVELOPMENT 3887
 Cold Spring Harbor Laboratory Press on November 10, 2010 - Published by genesdev.cshlp.orgDownloaded from 
References
Andrews, P. 1970. Estimation of molecular size and molecular
weights of biological compounds by gel filtration. Meth. Bio-
chem. Anal. 18: 1–53.
Carnero, A. and G. Hannon. 1998. The INK4 family of CDK
inhibitors. Curr. Top. Microbiol. Immunol. 227: 43–55.
Chen, J., P.K. Jackson, M.W. Kirschner, and A. Dutta. 1995.
Separate domains of p21 involved in the inhibition of Cdk
kinase and PCNA. Nature 374: 386–388.
Dulic, V., G. Stein, D. Far, and S. Reed. 1998. Nuclear accumu-
lation of p21Cip1 at the onset of mitosis: a role at the G2/
M-phase transition. Mol. Cell. Biol. 18: 546–557.
Harper, J. 1997. Cyclin dependent kinase inhibitors. Cancer
Surv. 29: 91–107.
Harper, J.W., S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.H. Tsai,
P. Zhang, S. Dobrowolski, C. Bai, C.L. Connell, E. Swindell,
M.P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent
kinases by p21. Mol. Biol. Cell. 6: 387–400.
Hengst, L. and S. Reed. 1998. Inhibitors of the Cip/Kip family.
Curr. Top. Microbiol. Immunol. 227: 25–41.
Hengst, L., V. Dulic, J.M. Slingerland, E. Lees, and S.I. Reed.
1994. A cell cycle-regulated inhibitor of cyclin-dependent
kinases. Proc. Natl. Acad. Sci. 91: 5291–5295.
Kriwacki, R., L. Hengst, L. Tennant, S. Reed, and P. Wright.
1996. Structural studies of p21Waf1/Cip1/Sdi1 in the free
and Cdk2-bound state: Conformational disorder mediates
binding diversity. Proc. Natl. Acad. Sci. 93: 11504–11509.
Li, Y., C.W. Jenkins, M.A. Nichols, and Y. Xiong. 1994. Cell
cycle expression and p53 regulation of the cyclin-dependent
kinase inhibitor p21. Oncogene 9: 2261–2268.
Luo, Y., J. Hurwitz, and J. Massague´. 1995. Cell-cycle inhibition
by independent CDK and PCNA binding domains in
p21Cip1. Nature 375: 159–161.
Morgan, D.O. 1995. Principles of CDK regulation. Nature
374: 131–134.
Nigg, E.A. 1995. Cyclin-dependent protein kinases: Key regula-
tors of the eukaryotic cell cycle. BioEssays 17: 471–480.
Noda, A., Y. Ning, S.F. Venable, S.O. Pereira, and J.R. Smith.
1994. Cloning of senescent cell-derived inhibitors of DNA
synthesis using an expression screen. Exp. Cell. Res.
211: 90–98.
Pines, J. 1995. Cyclins and cyclin-dependent kinases: A bio-
chemical view. Biochem. J. 308: 697–711.
Russo, A.A., P.D. Jeffrey, A.K. Patten, J. Massague, and N.P.
Pavletich. 1996. Crystal structure of the p27Kip1 cyclin-de-
pendent -kinase inhibitor bound to the cyclin A-Cdk2 com-
plex. Nature 382: 325–331.
Sheaff, R.J., M. Groudine, M. Gordon, J.M. Roberts, and B.E.
Clurman. 1997. Cyclin E-Cdk2 is a regulator of p27Kip1.
Genes & Dev. 11: 1464–1478.
Sherr, C.J. and J.M. Roberts. 1995. Inhibitors of mammalian G1
cyclin-dependent kinases. Genes & Dev. 9: 1149–1163.
Toyoshima, H. and T. Hunter. 1994. p27, a novel inhibitor of G1
cyclin-Cdk protein kinase activity, is related to p21. Cell
78: 67–74.
Vlach, J., S. Hennecke, and B. Amati. 1997. Phosphorylation-
dependent degradation of the cyclin-dependent kinase in-
hibitor p27Kip1. EMBO J. 16: 5334–5344.
Zhang, H., G.J. Hannon, and D. Beach. 1994a. p21-containing
cyclin kinases exist in both active and inactive states. Genes
& Dev. 8: 1750–1758.
Zhang, H., G.J. Hannon, D. Casso, and D. Beach. 1994b. p21 is
a component of active cell cycle kinases. Cold Spring Harbor
Symp. Quant. Biol. 59: 21–29.
Hengst et al.
3888 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on November 10, 2010 - Published by genesdev.cshlp.orgDownloaded from 
